Twist Bioscience Corp

CRISPR Therapeutics

Recursion Pharmaceuticals

Veracyte

Natera

CareDx

Adaptive Biotechnologies

Guardant Health Inc

Beam Therapeutics

Schrodinger 

ARK Genomic Revolution Multi-Sector ETF

ARKG is an actively managed fund that targets companies involved in the genomics industry.

ARK Web x.0 ETF

Invesco Solar ETF

iPath S&P 500 Dynamic VIX ETN

Few sector ETFs have doubled this year amid the coronavirus pandemic.

4 Sector ETFs That Have Doubled This Year

ARK Fintech Innovation ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

I recently discovered Cathie Wood and ARK Invest and have come away very impressed with their ETFs.

ARK Invest: The Best High-Growth ETFs That I'm Aware Of

First Trust NYSE Arca Biotechnology Index Fund

ALPS Medical Breakthroughs ETF

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biotechnology Index Fund were all up 1.4% at midday, dwarfing the 0.4% rise for the S&P 500.

Biotech ETFs at two-week highs on upbeat vaccine news

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Genomics ETFs have surged of late; here's why

Why You Should Invest in Genomics ETFs

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is a star among healthcare exchange traded funds this year and CRISPR is a big reason why. Looking at the long-term outlook, ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing.

How CRISPR Future Shapes Up for Hot Genomics ETF

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

Invesco Dynamic Biotechnology & Genome ETF

SPDR S&P Biotech ETF

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Biotech ETFs to Shine on Coronavirus Antibodies Progress

VanEck Rare Earth/Strategic Metals ETF

AXS Cannabis ETF

Wall Street registered back-to-back weekly gains primarily on the back of prospects for another round of fiscal stimulus from Congress.

5 Sector ETFs Gaining in Double Digits to Start October

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

Count long read DNA sequencing among the growing list of catalysts for the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). Long DNA is a new frontier in the genomics space, but it’s applications are critical given the role genetics play in treating an array of diseases.

Long Read DNA Sequencing Ready for its Moment. That’s Big for this ETF.

Virtus LifeSci Biotech Clinical Trials ETF

SPDR S&P Pharmaceuticals ETF

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Top-Performing Biotech ETFs Amid the Coronavirus Crisis

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is in rare air among healthcare exchange trade funds this year, having nearly doubled. Robust exposure to new and exciting therapies is one obvious catalyst for ARKG’s success.

Genomics ETF Continues to Thrill Investors

Breakwave Dry Bulk Shipping ETF

Global X Cannabis ETF

United States Oil Fund LP

We have highlighted the best and worst-performing zones and their ETFs in the first nine months of 2020.

Top & Flop ETF Zones of First Nine Months of 2020

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

There are rarely dull moments with the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) and most of the time, that’s a positive trait. That was the case for some of the exchange traded fund’s components last week.

Another Interesting Week for the Genomics ETF

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) continually offers investors exposure to new frontiers in the healthcare space. Add another to that growing list in the form long read sequencing shedding light on dark genes.

Dark Genes Shine Light on Genomics ETF Opportunity

Roundhill Sports Betting & iGaming ETF

Global X Telemedicine & Digital Health ETF

iShares U.S. Medical Devices ETF

Vanguard Health Care ETF

Direxion Work From Home ETF

Health Care Select Sector SPDR Fund

Global X's new telemedicine fund proves to be the right ETF for the right moment.

Sleeper Hit ETF Of 2020

The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) turns six years old next month and over that time, it’s developed a reputation as one of the best-performing healthcare ETFs, biotechnology or otherwise. That success is attributable to the ability of ARK Invest’s managers to identify disruptive genomics equities well before markets fully appreciate the growth [.

Why This Genomics ETF Is a Long-Term Winner

The fight against the novel coronavirus is putting plenty of healthcare ETFs in the spotlight this year, including the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG), but there’s much more to the ARKG story. In fact, ARKG was one of the best-performing healthcare ETFs prior to COVID-19 becoming part of the daily lexicon.

CRISPR Benefits Available in This Genomics ETF

The five actively managed ETFs from ARK Funds have driven impressive returns by investing in disruptive innovation.

ARKG: An ETF Using Disruptive Innovation To Drive Impressive Growth

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.

How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

Among ETFs focusing on disruptive themes, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is rarely short of compelling catalysts. ARKG includes companies that merge healthcare with technology and capitalize on the revolution in genomic sequencing.

Another Exciting Could Lift Long-Term Genomics Outlook

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

Investors looking for access to CRISPR gene editing technologies should consider the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG), one of the ETFs best-positioned in this fast growing arena. Looking ahead, CRISPR-based innovations to accelerate given the technology’s ease of use, cost-efficacy, growing body of research surrounding its safety, and AI-powered CRISPR nuclease selection tools.

Make the CRISPR Call With This Genomics ETF

ARK Invest currently offers some of the best performing ETFs over the past five years.

News for ARK Genomic Revolution Multi-Sector ETF ETF (ARKG)